The all-in-one platform to find and track your stocks and investments
Discover the features
Statistics
Market Cap
510 million
PE Ratio
-
Beta (volatility)
-
Earnings Per Share
-2.3
About
ISIN : US02157Q1094
operates as a clinical-stage biopharmaceutical company that engages in the psychiatry drug development business.
The company develops ALTO-100 for the treatment of patients with major depressive disorder (MDD) and...
Price
Performance Comparison
| Alto Neuroscience, Inc. | |
|---|---|
| 1 year return |
+278 %
|
| 5 years return | - |
Valuation
| Price to Book | Payout ratio | PEG Ratio |
|---|---|---|
| 4.63 | 0 % |
| Price to Sales | Price / FCF | E.V.R. |
|---|---|---|
| -8.64 | 0.00 |
Price–Earnings Ratio History
The Price–Earnings Ratio history is not available for this stock.
Dividend History
It looks like no dividends is being distributed for this stock...
Number of Outstanding Shares
Financials
Year-over-Year growth
Profitability
Health
Create a portfolio & add this stock
Add this stock and others to your own virtual portfolio and get personalised information : total annual dividends & total value, sectors breakdown, etc.
Privacy Policy • Terms and Conditions
© Copyright 2020-2026 Epsylia OÜ - All rights reserved
Moning is a platform that does not manage any funds and is purely educational. We do not provide any investment advice.
The data presented comes from different providers and may contain errors. We encourage you to always verify information through other sources.
Any financial investment involves risks including partial or total loss of capital.
The data presented comes from different providers and may contain errors. We encourage you to always verify information through other sources.
Any financial investment involves risks including partial or total loss of capital.